DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016" report to their offering.
Macrophage Migration Inhibitory Factor pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2016, outlays comprehensive information on the Macrophage Migration Inhibitory Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Macrophage Migration Inhibitory Factor targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
Key Topics Covered:
- Introduction
- Macrophage Migration Inhibitory Factor Overview
- Therapeutics Development
- Pipeline Products for Macrophage Migration Inhibitory Factor - Overview
- Pipeline Products for Macrophage Migration Inhibitory Factor - Comparative Analysis
- Macrophage Migration Inhibitory Factor - Therapeutics under Development by Companies
- Macrophage Migration Inhibitory Factor - Therapeutics under Investigation by Universities/Institutes
- Macrophage Migration Inhibitory Factor Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Macrophage Migration Inhibitory Factor - Products under Development by Companies
- Macrophage Migration Inhibitory Factor - Products under Investigation by Universities/Institutes
- Macrophage Migration Inhibitory Factor - Companies Involved in Therapeutics Development
- Kyorin Pharmaceutical Co., Ltd.
- PDS Biotechnology Corporation
-
Shire Plc
For more information about this report visit http://www.researchandmarkets.com/research/n4hnvd/macrophage